{"id":10839,"date":"2026-07-10T17:45:02","date_gmt":"2026-07-10T15:45:02","guid":{"rendered":"https:\/\/www.ab-science.com\/?p=10839"},"modified":"2026-07-10T17:47:53","modified_gmt":"2026-07-10T15:47:53","slug":"ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques","status":"publish","type":"post","link":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/","title":{"rendered":"AB Science fait le point sur son programme clinique avec l\u2019arr\u00eat de certaines \u00e9tudes cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]<\/p>\n<h3 class=\"Default\">10\/07\/2026 \u2013\u00a0AB Science fait aujourd\u2019hui le point sur son programme de d\u00e9veloppement clinique et annonce l\u2019arr\u00eat de certaines \u00e9tudes clinique non prioritaires, en vue de se concentrer sur deux programmes cliniques, le programme AB8939 dans la LMA et le programme masitinib dans la SLA<\/h3>\n<h3 class=\"Default\"><\/h3>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]<iframe width=\"100%\" height=\"800\" src=\"https:\/\/www.ab-science.com\/themencode-pdf-viewer-sc\/?tnc_pvfw=ZmlsZT1odHRwczovL3d3dy5hYi1zY2llbmNlLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNi8wNy9DbGluaWNhbC1Qcm9ncmFtLVVwZGF0ZS1KdWx5LTIwMjYtVkZSLVZGLnBkZiZzZXR0aW5ncz0xMTEwMTExMTExMTExMTExMTAwJmxhbmc9ZW4tVVM=#page=&zoom=100&pagemode=none\" title=\"\"><\/iframe>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">#default-btn-5991e67086cc541048cc7256120c01e7.ico-right-side > i {\n  margin-right: 0px;\n  margin-left: 8px;\n}\n#default-btn-5991e67086cc541048cc7256120c01e7 > i {\n  margin-right: 8px;\n}<\/style><div class=\"btn-align-center\"><a href=\"https:\/\/www.ab-science.com\/wp-content\/uploads\/2026\/07\/Clinical-Program-Update-July-2026-VFR-VF.pdf\" class=\"default-btn-shortcode dt-btn dt-btn-l link-hover-off  vc_custom_1783698376226\" target=\"_blank\" id=\"default-btn-5991e67086cc541048cc7256120c01e7\" rel=\"noopener\"><i class=\"dt-icon-the7-download\"><\/i><span>T\u00e9l\u00e9charger le PDF<\/span><\/a><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb] 10\/07\/2026 \u2013\u00a0AB Science fait aujourd\u2019hui le point sur son programme de d\u00e9veloppement clinique et annonce l\u2019arr\u00eat de certaines \u00e9tudes clinique non prioritaires, en vue de se concentrer sur deux programmes cliniques, le programme AB8939 dans la LMA et le programme masitinib dans la SLA [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[138],"tags":[],"class_list":["post-10839","post","type-post","status-publish","format-standard","hentry","category-2026-fr","category-138","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AB Science fait le point sur son programme clinique avec l\u2019arr\u00eat de certaines \u00e9tudes cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB Science fait le point sur son programme clinique avec l\u2019arr\u00eat de certaines \u00e9tudes cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb] 10\/07\/2026 \u2013\u00a0AB Science fait aujourd\u2019hui le point sur son programme de d\u00e9veloppement clinique et annonce l\u2019arr\u00eat de certaines \u00e9tudes clinique non prioritaires, en vue de se concentrer sur deux programmes cliniques, le programme AB8939 dans la LMA et le programme masitinib dans la SLA [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-10T15:45:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-10T15:47:53+00:00\" \/>\n<meta name=\"author\" content=\"Alexis BERNARD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis BERNARD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\\\/\"},\"author\":{\"name\":\"Alexis BERNARD\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\"},\"headline\":\"AB Science fait le point sur son programme clinique avec l\u2019arr\u00eat de certaines \u00e9tudes cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques\",\"datePublished\":\"2026-07-10T15:45:02+00:00\",\"dateModified\":\"2026-07-10T15:47:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\\\/\"},\"wordCount\":176,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"articleSection\":[\"2026\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\\\/\",\"name\":\"AB Science fait le point sur son programme clinique avec l\u2019arr\u00eat de certaines \u00e9tudes cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2026-07-10T15:45:02+00:00\",\"dateModified\":\"2026-07-10T15:47:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB Science fait le point sur son programme clinique avec l\u2019arr\u00eat de certaines \u00e9tudes cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\",\"name\":\"Alexis BERNARD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"caption\":\"Alexis BERNARD\"},\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/author\\\/abernard\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AB Science fait le point sur son programme clinique avec l\u2019arr\u00eat de certaines \u00e9tudes cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/","og_locale":"fr_FR","og_type":"article","og_title":"AB Science fait le point sur son programme clinique avec l\u2019arr\u00eat de certaines \u00e9tudes cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques","og_description":"[vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb] 10\/07\/2026 \u2013\u00a0AB Science fait aujourd\u2019hui le point sur son programme de d\u00e9veloppement clinique et annonce l\u2019arr\u00eat de certaines \u00e9tudes clinique non prioritaires, en vue de se concentrer sur deux programmes cliniques, le programme AB8939 dans la LMA et le programme masitinib dans la SLA [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=\u00a0\u00bb\u00a0\u00bb][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]","og_url":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/","og_site_name":"AB Science","article_published_time":"2026-07-10T15:45:02+00:00","article_modified_time":"2026-07-10T15:47:53+00:00","author":"Alexis BERNARD","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Alexis BERNARD","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/#article","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/"},"author":{"name":"Alexis BERNARD","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755"},"headline":"AB Science fait le point sur son programme clinique avec l\u2019arr\u00eat de certaines \u00e9tudes cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques","datePublished":"2026-07-10T15:45:02+00:00","dateModified":"2026-07-10T15:47:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/"},"wordCount":176,"publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"articleSection":["2026"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/","url":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/","name":"AB Science fait le point sur son programme clinique avec l\u2019arr\u00eat de certaines \u00e9tudes cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2026-07-10T15:45:02+00:00","dateModified":"2026-07-10T15:47:53+00:00","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"AB Science fait le point sur son programme clinique avec l\u2019arr\u00eat de certaines \u00e9tudes cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]},{"@type":"Person","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755","name":"Alexis BERNARD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","caption":"Alexis BERNARD"},"url":"https:\/\/www.ab-science.com\/fr\/author\/abernard\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/10839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=10839"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/10839\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=10839"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/categories?post=10839"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/tags?post=10839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}